期刊文献+

美洛昔康凝胶治疗AA大鼠的疗效与局部药物浓度的关系研究 被引量:6

The relationship between therapeutic effects and concentration in tissue or serum of Mel G
在线阅读 下载PDF
导出
摘要 目的 探讨美洛昔康凝胶 (MelG)对佐剂性关节炎(AA)大鼠的治疗作用以及治疗效果与MelG血药浓度和局部药物浓度之间的关系。方法 采用FCA诱导大鼠AA ,用Volumemeter测定大鼠足爪容积 ,用HPLC测定MelG的血药浓度和足爪局部药物浓度 ,将足爪肿胀度与MelG的血药浓度或局部药物浓度作相关分析。结果 MelG明显抑制AA大鼠继发性炎症 ,MelG组大鼠血药浓度低于Mel组 ,足爪局部药物浓度则明显高于Mel组 ;AA大鼠继发性足爪肿胀度与MelG的足爪局部药物浓度间呈显著负相关。结论 MelG对AA大鼠的治疗作用与其足爪局部药物浓度高有关。 Aim To study the effects of Meloxicam gel(Mel G)on AA in rats,and the relationship between therapeutic effects and Mel G in tissue or serum. Methods The model of AA was induced by intradermal injection of Freunds complete adjuvant(FCA) in rats,the effects(hindpaw swelling volume)of Mel G on AA rats were observed following Mel G tc. A high performance liquid chromatography(HPLC)method with ultraviolet detection was set up to determine the concentration of Mel in serum and local tissue. Results Mel G significantly inhibited secondary inflammation of AA rats. The concentration of Mel G was lower in serum and higher in local tissue than that of Mel tablets. A significant linear correlation in a negative manner existed between local tissue concentration of Mel G and hindpaw swelling volume. Conclusion Therapeutic effects of Mel G on AA in rats were associated with higher tissue concentration of Mel G.
出处 《中国药理学通报》 CAS CSCD 北大核心 2004年第8期890-893,共4页 Chinese Pharmacological Bulletin
关键词 美洛昔康 佐剂性关节炎 透皮给药 HPLC 大鼠 meloxicam adjuvant arthritis transdermal administration HPLC rat
  • 相关文献

参考文献8

  • 1谭伟.类风湿性关节炎的用药问题[J].医药导报,1997,16(3):142-142.
  • 2Engelhardt G,Homma D,Schlegel K et al. General pharmacology of meloxicam-Part I:Effects on CNS, gastric emptying, intestinal transport, water, electrolyte and creatinine excretion[J]. Gen Pharmacol,1996,27(4): 673-7.
  • 3Schoenfeld P. Gastrointestinal safety profile of meloxicam:A meta-analysis and systematic review of randomized controlled trials[J]. Am J Med,1999,107(6A):48-54.
  • 4胡成穆,金涌,姚宏伟,李俊.美洛昔康凝胶剂对佐剂性关节炎大鼠的治疗作用[J].安徽医科大学学报,2002,37(2):105-107. 被引量:3
  • 5陈敏珠.抗炎药物筛选规程[M].见:周金黄主编.药理学进展[C].北京:人民卫生出版社,1991.713-23.
  • 6夏运岳,潘建新,顾振纶.美洛昔康在大鼠体内的药代动力学研究[J].中国药理学通报,2001,17(2):236-237. 被引量:6
  • 7李俊,张运芳,汤晓林,李常玉,徐叔云.尼美舒利对佐剂性关节炎大鼠的治疗作用[J].安徽医科大学学报,1996,31(5):381-383. 被引量:4
  • 8Ogino K,Hatanaka K,Kawamura M et al. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1[J]. Pharmacol,1997,55(1):44-53.

二级参考文献10

  • 1魏伟.Roferon-A(基因重组α-2α干扰素)[J].中国药理学通报,1989,5(4). 被引量:1
  • 2李运曼,李娟,杨贵成,李璐.萘普生凝胶剂与片剂的抗炎作用比较[J].中国药科大学学报,1996,27(12):738-738. 被引量:3
  • 3陈敏珠 周金黄.抗炎药物筛选规程.药理学进展[M].北京:人民卫生出版社,1991.713-723.
  • 4裴德凯 卞如濂 等.胃病的实验模型.药理实验方法学(第二版)[M].北京:人民卫生出版社,1991.1157-1160.
  • 5[1]Engel-Hardt G,bogel R,Schnitzler C et al.Meloxicam:A new NSAID with an improved safety profile through preferential inhibition of cox-2. Biochem Pharmacol,1996;51(1):21~8
  • 6[2]Justuro C,Cauirke JF.Dose response relationship for the antipyretic effect of meloxicam in an endotoxin model in cats. Vet Res Commrn,1995;19(4):321~30
  • 7[3]Trck D,Busch U,Heinzel G el al.ClinicalPharmacokinetics of Meloxicam. Arzneim Forsch,1997;47(1):253~8
  • 8[4]Schmid J,Busch U,Heinzel G et al.Pharmacokinetics and Metabolic Pattern of Meloxicam. Drug Metabolism and Disposition,1995;23(11):1206~13
  • 9[5]Picot D,Loll PT,Garavito RM.The X-ray crystal structure of the membrane protein prostagland in Hzsynthase-1.Nature,1994;367(6460):243~9
  • 10何庆,周亚雄,许树耘,秦莉,沈文雅,邓绪乐.双氯芬酸钾凝胶剂治疗急性疼痛和安全性评价[J].华西药学杂志,2000,15(6):467-468. 被引量:4

共引文献12

同被引文献88

引证文献6

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部